Prothena (PRTA) Scheduled to Post Quarterly Earnings on Wednesday

Prothena (NASDAQ:PRTA) will be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.03). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $2.15 million. During the same period in the previous year, the firm earned $0.12 EPS. The firm’s revenue was down 99.4% on a year-over-year basis. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Prothena Stock Down 0.6 %

Shares of PRTA stock traded down $0.14 during midday trading on Tuesday, reaching $23.60. 26,823 shares of the company were exchanged, compared to its average volume of 729,138. The company’s 50 day moving average price is $24.56 and its two-hundred day moving average price is $30.70. Prothena has a 12 month low of $19.65 and a 12 month high of $79.38.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PRTA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research note on Wednesday, April 10th. JMP Securities increased their target price on Prothena from $81.00 to $85.00 and gave the stock a “market outperform” rating in a report on Friday, February 16th. Oppenheimer reduced their price target on shares of Prothena from $98.00 to $80.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 20th. Royal Bank of Canada lowered their price objective on Prothena from $36.00 to $35.00 and set a “sector perform” rating for the company in a research report on Friday, February 16th. Finally, Bank of America reissued a “neutral” rating and issued a $38.00 price target (down previously from $68.00) on shares of Prothena in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.14.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.